He Jin, Ma Chuncai, Wang Fangnan
Division of Nephrology and Endocrinology, Chonggang General Hospital, Chongqing 400016, P.R. China.
Med Int (Lond). 2022 May 31;2(3):18. doi: 10.3892/mi.2022.43. eCollection 2022 May-Jun.
Regional citrate anticoagulation (RCA) has been widely used in patients with high-risk bleeding for anticoagulation in renal replacement therapy. However, scientific reports on the use of RCA in double-filtration plasmapheresis (DFPP) are limited. In the available reports, anticoagulation was not performed in the plasma component separator. However, as demonstrated in the present study, during the treatment of a patient with anti-neutrophil cytoplasmic antibody-associated vasculitis, although RCA was used for DFPP, coagulation occurred in the plasma component separator, resulting in the interruption of treatment. Thus, segmental citrate anticoagulation (SCA) was used and the filter was successfully prevented from clotting again. The present study demonstrates that SCA can more effectively prevent the clogging of the plasma separator and the plasma component separator, thereby maintaining the continuity of treatment and avoiding treatment interruption.
局部枸橼酸盐抗凝(RCA)已广泛应用于肾替代治疗中具有高出血风险的患者进行抗凝。然而,关于在双重滤过血浆置换(DFPP)中使用RCA的科学报告有限。在现有报告中,血浆成分分离器未进行抗凝。然而,如本研究所示,在治疗一名抗中性粒细胞胞浆抗体相关性血管炎患者时,尽管在DFPP中使用了RCA,但血浆成分分离器仍发生凝血,导致治疗中断。因此,采用了分段枸橼酸盐抗凝(SCA),成功防止滤器再次凝血。本研究表明,SCA可以更有效地防止血浆分离器和血浆成分分离器堵塞,从而维持治疗的连续性并避免治疗中断。